Mast Therapeutics (MSTX) Reports In-Line Q2 EPS

Mast Therapeutics (NYSE: MSTX) reported Q2 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Mast Therapeutics (MSTX) click here.

You May Also Be Interested In

• AngioDynamics (ANGO) Tops Q4 EPS by 2c ; Offers Guidance
• Buy Apple stock ahead of expected $200 iPhone price hikes: Morgan Stanley
• Beam Global reports Q2 2026 revenue above $8.5M, up 170% from Q1